Company profile: StemCyte
1.1 - Company Overview
Company description
- Provider of umbilical cord blood stem cell transplantation and therapeutic products, offering cord blood and cord tissue banking, access to a public inventory of donated cord blood units, private banking for families, newborn genetic analysis screening for 200+ disorders, and HLA testing to identify compatibility with family members.
Products and services
- Public Bank Access: Delivers access to a public inventory of donated cord blood units for transplantation needs, connecting patients with available units sourced from banked donations
- Donor-sourced. Cord Blood Banking: Delivers preservation of a newborn’s umbilical cord blood stem cells for potential future medical treatments, maintaining a stored reserve for later therapeutic use
- Cord blood-derived. Private Banking Service: Offers families the ability to privately bank their newborn’s stem cells for exclusive use, safeguarding access for personal treatment needs over time
- Family-exclusive.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to StemCyte
SimplicityBio
HQ: Switzerland
Website
- Description: Provider of in-silico biomarker discovery programmes for companies and institutions, offering services in biomarker discovery and ranking, signature creation, and existent signature, delivering robust multi-biomarker signatures for the molecular diagnostic market.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SimplicityBio company profile →
ProteinSimple
HQ: United States
Website
- Description: Provider of protein tools and analysis solutions that help researchers resolve protein analysis problems to reveal insights into proteins and their role in disease; part of the Protein Platforms division of Bio-Techne (NASDAQ: TECH).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ProteinSimple company profile →
Origimm Biotechnology
HQ: Austria
Website
- Description: Provider of biotechnology research specializing in discovery of antigens and functional drug targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Origimm Biotechnology company profile →
GenScript
HQ: United States
Website
- Description: Provider of contract research services specialized in biological research and drug discovery/development, offering gene synthesis with expression optimization, cloning and subcloning, plasmid DNA preparation for research, industrial and clinical applications, custom CRISPR-Cas9 gene editing, peptide synthesis, and ToxinSensor kits for sensitive, low-cost endotoxin detection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenScript company profile →
BAC
HQ: United States
Website
- Description: Provider of affinity purification products and services for the biopharmaceutical market, with CaptureSelect products used from drug discovery to manufacturing of biopharmaceuticals, based on a proprietary platform integrating affinity ligand discovery, manufacturing and immobilization of single domain antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BAC company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for StemCyte
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to StemCyte
2.2 - Growth funds investing in similar companies to StemCyte
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for StemCyte
4.2 - Public trading comparable groups for StemCyte
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →